Cheng Weishi, Sun Xu, Yang Shijie, Kang Kai, Wang Li, Han Chang, Wu Yijun, Zhao Ailin, Niu Ting
Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Ann Hematol. 2025 Jun 19. doi: 10.1007/s00277-025-06445-4.
Pediatric Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are distinct from adult forms and occur less frequently. We identified 7,871 children and 226,211 adults with lymphoma from the Surveillance, Epidemiology, and End Results database from 1975 to 2018. The age-adjusted incidence rate for pediatric lymphoma was 24.5 per million persons (95% CI: 24.0-25.1), comprising 13.0 per million (95% CI: 12.6-13.4) for HL and 11.5 per million (95% CI: 11.1-11.9) for NHL. In comparison to adult lymphoma, pediatric lymphoma showed no significant changes in incidence from 1975 to 2002 (annual percentage change, APC = -0.12 ± 0.19, P = 0.53), but displayed an observable increase after 2003 (APC = + 1.31 ± 0.45, P = 0.006). Among pediatric cases, the 5-year limited-duration prevalence rate increased from 0.00691% in 1996 to > 0.009% in recent years, and the 20-year rate rose from 0.0109% in 1996 to 0.0148% in 2018. In alignment with the observed decrease in incidence over the recent decade, the prevalence of adult lymphoma exhibited a more gradual growth post-2007. Among adult patients, the age-adjusted mortality rate demonstrated an initial increase in the periods 1975-1977 (APC = + 41.06 ± 6.23, P < 0.001), 1977-1980 (APC = + 9.83 ± 4.27, P = 0.036), 1980-1989 (APC = + 5.24 ± 0.36, P < 0.001), and 1989-1994 (APC = + 2.27 ± 0.86, P = 0.014), followed by a subsequent decrease after 1994 (APC= -0.49 ± 0.05, P < 0.001). In contrast, the mortality rates of pediatric lymphoma exhibited a consistent decrease over the past four decades (1975-2018: APC= -3.12 ± 0.29, P < 0.001), resulting in an overall age-adjusted mortality rate of 2.92 (95% CI: 2.73-3.11).
儿童霍奇金淋巴瘤（HL）和非霍奇金淋巴瘤（NHL）与成人形式不同，且发病率较低。我们从1975年至2018年的监测、流行病学和最终结果数据库中识别出7871名儿童和226211名成人淋巴瘤患者。儿童淋巴瘤的年龄调整发病率为每百万人24.5例（95%置信区间：24.0 - 25.1），其中HL为每百万人13.0例（95%置信区间：12.6 - 13.4），NHL为每百万人11.5例（95%置信区间：11.1 - 11.9）。与成人淋巴瘤相比，儿童淋巴瘤在1975年至2002年发病率无显著变化（年百分比变化，APC = -0.12 ± 0.19，P = 0.53），但在2003年后呈现出明显上升（APC = +1.31 ± 0.45，P = 0.006）。在儿童病例中，5年有限期患病率从1996年的0.00691%上升至近年来的>0.009%，20年患病率从1996年的0.0109%上升至2018年的0.0148%。与近十年来观察到的发病率下降相一致，成人淋巴瘤患病率在2007年后呈现出更为缓慢的增长。在成年患者中，年龄调整死亡率在1975 - 1977年（APC = +41.06 ± 6.23，P < 0.001）、1977 - 1980年（APC = +9.83 ± 4.27，P = 0.036）、1980 - 1989年（APC = +5.24 ± 0.36，P < 0.001）和1989 - 1994年（APC = +2.27 ± 0.86，P = 0.014）期间最初有所上升，随后在1994年后下降（APC = -0.49 ± 0.05，P < 0.001）。相比之下，儿童淋巴瘤死亡率在过去四十年（1975 - 2018年：APC = -3.12 ± 0.29，P < 0.001）持续下降，总体年龄调整死亡率为2.92（95%置信区间：2.73 - 3.11）。
